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Abstract
Background Simple enucleation (SE) has proven to be
oncologically safe. We describe the surgical steps and
report the results of the Endoscopic Robotic-Assisted
Simple Enucleation (ERASE) technique.
Methods Data were gathered prospectively from 130
consecutive patients undergone ERASE for intracapsular
kidney cancer, between 2010 and 2013. ERASE was per-
formed using the 4S Da Vinci surgical system, (Intuitive
Surgical, Sunnyvale, CA, USA) in a three-arm configura-
tion. Patients’ characteristics and surgical outcomes of
ERASE in cT1 were analyzed and the results in cT1a
tumors were compared to those of pure laparoscopic SE
performed in the same institution in the same time period.
Results The mean (range) preoperative tumor size was
3.2 cm (0.8–10.0 cm), and clinical stage was T1a for 101
patients, T1b for 28, and T2a for 1. Median PADUA score was
8 (IQR 7–9). In 33.9 % of patients, ERASE was done without
pedicle clamping. Mean (±SD) warm ischemia time (WIT)
was 18 ± 6 min. According to Clavien system, 1 grade 1
(0.8 %), 5 grade 2 (3.1 %), 4 grade 3 (3.8 %), and 1 grade 4
(0.8 %) surgical complications occurred. Positive surgical
margin (PSM) rate was 2.8 %. ERASE in cT1a tumors was
associated with a significantly lower need for pedicle clamp-
ing, shorter WIT, and lower estimated blood loss (EBL) along
with similar operative time and intra and postoperative com-
plication rates but with a significantly lower incidence of
urinary fistulas requiring stent insertion compared to laparo-
scopic SE. Also mean time to drainage removal and length of
hospital stay (LOS) were significantly lower in for ERASE.
The two groups had comparable PSM rate.
Conclusions ERASE has proven to be a feasible tech-
nique for the minimal invasive treatment of clinical stage
T1 renal masses. The robotic approach can achieve surgical
results superior to those of pure laparoscopy by reducing
the need for clamping, WIT, EBL, and LOS.
Keywords Partial nephrectomy  Peritumoral capsule 
Renal cell carcinoma  RAPN  Robotic partial
nephrectomy  Simple enucleation
Partial nephrectomy (PN) with a minimal tumor-free surgical
margin is considered the gold standard technique of NSS to
minimize the risk of local recurrence [1, 2]. In this scenario,
some studies have supported the oncological efficacy of the
simple enucleation (SE) technique, defined as the blunt exci-
sion of the tumor without a visible margin, following the nat-
ural cleavage plane between the tumor capsule and healthy
parenchyma. Prospective studies confirmed the SE safety from
a pathological perspective [3] and large retrospective series
showed its oncological equivalence to standard PN [4–6].
Data from the largest comparative study between open
PN (OPN) and laparoscopic PN (LPN) found LPN to be a
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technically feasible, safe, and effective option in selected
patients with RCC who are candidates for a nephron-
sparing procedure. However, although LPN has the
advantages of the minimal invasiveness and it is able to
duplicate the open technique with excellent results, it still
remains a technically challenging procedure both for the
extirpative and reconstructive phase [7–9].
First reported in 2004 by Gettman et al. robot-assisted
partial nephrectomy (RAPN) using the da Vinci Surgical
System (Intuitive Surgical, CA, USA) represents an alter-
native procedure to LPN and OPN for the treatment of
intracapsular RCCs and has steadily gained acceptance
between surgeons [10]. Early feasibility studies have
demonstrated that RAPN provides equivalent oncological
results to LPN with the further advantage of significantly
lower intraoperative blood loss, reduced hospital stay, and
WIT [11]. Recent studies have also shown that RAPN can
be effectively utilized for the treatment of larger renal
tumors that are over 4 cm in diameter and in cases of
parahilar lesions [12–15]. Indeed, the 3D vision associated
with the ‘endowrist’ technology allows for excellent vision
of the operative field and the possibility of dissecting the
tissue optimally by varying the degree of incidence with
the target structures.
In this video we present our surgical technique for the
treatment of clinically localized renal masses: the Endo-
scopic Robotic-Assisted Simple Enucleation (ERASE).
It represents the robotic translation of the SE technique,
developed in our center over 25 years ago and become the
standard of care for NSS either open and laparoscopically
[5, 6, 16–18].
Materials and methods
After institutional review board approval was obtained,
data were gathered prospectively from 130 consecutive
patients who had ERASE and from 67 patients who had
laparoscopic SE for intracapsular kidney cancer, between
January 2010 and January 2013. Preoperative assessment
included blood count, liver function test, serum creatinine,
electrolytes. Abdominal CT scan with contrast medium and
3D reconstruction or angio-MRI were used to delineate the
vascular anatomy, tumor size, spatial development,
involvement of the collecting system, and relationship with
the renal sinus. All patients were scored according to the
PADUA nephrometric classification [19].
Surgical techniques
A detailed illustration of the surgical techniques for
ERASE employed at our institutions can be found in the
accompanying video material.
For the present series of ERASE we used the 4S Da
Vinci robot, (Intuitive Surgical, Sunnyvale, CA, USA),
always in a three-arm configuration with a 30 laparoscope.
Laparoscopic SE was performed using a 2D full HD KARL
STORZ 30 camera and HD monitor. The transperitoneal
approach was always preferred, with the exception of
tumors with posterior location, or previous complicated
transperitoneal surgery.
Transperitoneal approach
For the transperitoneal approach, the patient was positioned
in the flank position, elevated at approximately 70.
Pneumoperitoneum was created using a standard mini-open
access. One 12-mm trocar for the camera plus two 8-mm
ports for the robotic instruments (Hasson trocar and two
10-mm trocars for the laparoscopic procedure) were used,
one in mid-clavicular line 3 cm below the costal margin,
and another one, caudally and on the same line to obtain an
optimal triangulation. According the complexity of the
case and patients’ configuration one or two additional
trocars were inserted (Fig. 1).
The standard transperitoneal approach was then fol-
lowed: the peritoneum is incised along the line of Told and
the bowel medialized. Once the Gerota’s fascia is incised,
progressively all landmarks are identified. Subsequently,
the kidney is totally freed from the fatty tissue to clearly
delineate the limits of the tumor and to detect satellite
lesions. In case of posterior tumors the kidney was rotated
in order to perform comfortably the extirpative and
reconstructive phase. According to the surgeon’s prefer-
ence warm ischemia was obtained with an en-bloc pedicle
or a selective/superselective arterial bulldog-clamp.
Retroperitoneal approach
For the retroperitoneal approach, the patient was positioned
in flank position, elevated at approximately 90.
After the open access at the level of the mid-iliac crest,
the finger tip is used to mobilize the peritoneum and to
create the retroperitoneal space.
For ERASE, a 4-port technique is used, including one
12-mm trocar for the camera at the level of the first inci-
sion, two 8-mm trocars for the robotic arms: the first placed
at the level of the lateral border of the peritoneal reflection,
the second one at the lateral border of the paraspinal
muscles and a 12-mm trocar for the assistant is placed on
the anterior axillary line between the camera and one of the
robotic arm (Fig. 1).
For the laparoscopic approach, again a 4-port technique
is used, including three 10-mm trocars, the first placed at
the level of the mid-iliac crest, the second one at the lateral
border of the paraspinal muscles, and the third at the
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Fig. 1 Port configuration used
during ERASE.
A Transperitoneal approach port
placement. B Retroperitoneal
approach port placement.
c = 12-mm port for the robotic
scope; r = 8-mm ports for the
robotic instruments; a = 12-
mm and 5-mm port for the
assistant
Fig. 2 Intraoperative views showing: Cautery marking (A) and
incision of kidney parenchyma 1 or 2 mm away from the lesion
(B). Widening of the space between healthy tissue and kidney tumor
with monopolar scissors and bipolar dissector (C). The natural
cleavage plane between kidney parenchyma and tumor capsule is
followed by blunt dissection (D–F)
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anterior axillary line at the lateral border of the peritoneal
reflection. A 5-mm trocar is inserted at the tip of the 12th
rib.
Intraoperative ultrasonography was used during this
period only in case of completely endorenal masses.
Endoscopic Robotic-Assisted Simple Enucleation (ERASE)
and laparoscopic SE
To prevent ischemic renal damage, all patients were
hydrated and infused with mannitol a few minutes before
arterial clamping to minimize intracellular swelling.
To obtain warm ischemia an en-bloc pedicle or a
selective/superselective arterial bulldog-clamp is placed.
A clamp less technique was chosen based on the size,
site, and growth pattern of the tumor and indications for
surgery.
Once the tumor is isolated, its limits are clearly identi-
fied and the excision template is marked with cautery,
1–2 mm away from the lesion. The kidney is sharply
incised toward the tumor margins and when the tumor
capsule is visually identified, the tumor is enucleated by
blunt dissection, with no visible rim of normal parenchyma
around it (Fig. 2). The preferred instruments used during
ERASE were monopolar scissors on the right and prograsp/
Maryland grasper on the left. Suction was provided by the
table assistant while the preferred instruments used by the
first operator during laparoscopic SE were monopolar
scissors and suction device. Hemostasis was then con-
trolled either by a knot-tying suture repair (standard-LNSS)
or by a sutureless technique (s-LNSS) according to the
intraoperative findings.
Hemostasis was then controlled by one or two 2-0
monofilament running sutures on the parenchymal bed with
the hemlock placed on the kidney capsule at the begin-
ning and at the end of the suture. Approximation of the
renal capsule defect over Floseal and Tabotamp bolster
was obtained with a sliding clip 2-0 Vicryl single suture.
Alternatively, Tachosil apposition was used without the
approximation of the renal capsule, mainly in case of wide
and not deep resection beds (Fig. 3).
When approaching small cortical lesions a sutureless
hemostasis was done using a bipolar cauterization of the
resection bed, followed by Floseal or Tachosil 
apposition.
Fig. 3 A sliding clip approximation of the renal capsule defect over Floseal and Tabotamp bolster (A). Tachosil apposition without the
approximation of the renal capsule (B)
Table 1 Patient demographics and preoperative parameters
Age, year; mean (SD) 61.8 (11.3)
Sex, no. (%)
Male 76 (58.5 %)
Female 54 (41.5 %)
BMI, median (IQR) 25.7 (23.4–28.3)
ASA score, no. (%)
0–2 116 (89.2 %)
3 14 (10.8 %)
Charlson index, median (IQR) 1 (0–1)
Clinical diameter, cm, mean (SD) 3.2 (1.5)
Clinical T stage, no. (%)
cT1a (B4 cm) 101 (77.7)
cT1b (4–7 cm) 28 (21.5)
cT2a (7–10 cm) 1 (0.8)
PADUA score, median (IQR) 8 (7–9)
Padua scores C8, no. (%) 42 (32.3 %)
Padua scores C10, no. (%) 10 (7.7 %)
Indication, no. (%)
Absolute/relative 9 (6.9 %)
Elective 121 (93.1 %)
Preoperative hemoglobin, g/dl, median (IQR) 14.1 (1.5)
Preoperative creatinine, mg/dl, median (IQR) 0.86 (0.30)
BMI body mass index, ASA American Society of Anesthesiologists
class risk, SD standard deviation, IQR interquartile range
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An early unclamping technique was always adopted in
case of arterial occlusion with the bulldog-clamp. In such
cases, the bulldog-clamp was removed always at the end of
the medullar reconstructive phase.
Results
Patients and tumors characteristics in the ERASE group are
summarized in Table 1.
The mean preoperative tumor size was 3.2 cm with a
range between 0.8 and 10.0 cm, and clinical stage was T1a
for 101 (77.7 %) patients, T1b for 28 (21.5 %), and T2a for
1 (0.8 %) patient. Median PADUA score resulted 8 (IQR
7–9), and it was C10 in 10 (7.7 %) patients. Indication was
elective for 121 (93.1 %) patients, and relative/imperative
for 9 (6.9 %).
Intraoperative data are reported in Table 2. In 44
patients (33.9 %), ERASE was done with no pedicle
clamping. Clamping was used in 86 (66.1 %) patients,
among them pedicle clamping was used in 72 (83.7 %),
with a mean ± SD warm ischemia time (WIT) of
18 ± 6 min; while the selective clamping of the isolated
arterial branch of the tumor was used in 14 (16.3 %)
patients. Overall, 20 patients (15.4 %) had WIT [25 min.
Mean (range) operative time (including the console time)
resulted 158 ± 56 min, mean ± SD estimated blood loss
(EBL) was 119 ± 105 cc. Intraoperative transfusion for
bleeding was required in 1 patient (0.8 %) with low pre-
operative hemoglobin (9 mg/dl).
Postoperative results are summarized in Table 3. Over-
all, postoperative complications occurred in 16/130 patients
(12.3 %); of these, 11 (8.5 %) were surgical and 5 (3.8 %)
medical. Surgical complications included blood loss treated
with transfusions in 5 (3.8 %) patients, with selective
arterial embolization in 3 (2.3 %), and with reoperation to
achieve hemostasis in 1 (0.8 %). Urinary fistula occurred in
1 patient (0.8 %) and was treated with bedrest and antibi-
otics, No patient needed ureteral stenting in this series. One
patient underwent reoperation due to spleen rupture, and
was treated with splenectomy. According to Clavien sys-
tem, 1 surgical complication was grade 1 (0.8 %), 5 grade 2
(3.1 %), 4 grade 3 (3.8 %), and 1 grade 4 (0.8 %).
Table 2 Intraoperative outcomes
Clamping, no. (%) 86 (66.1 %)
Pedicle/renal artery 72 (83.7 %)
Arterial branch/es 14 (16.3 %)
No clamping, no. (%) 44 (33.9 %)
WIT of pedicle/renal artery clamping, min, mean (SD) 18 (6)
WIT [25 min, no. (%) 20 (15.4 %)
Estimated blood loss, ml, mean (SD) 119 (105)
Operating time, min, mean (SD) 158 (56)
Total intraoperative complications, no. (%) 1 (0.8 %)
Transfusion 1 (0.8 %)
Pleural damage –
Spleen damage –
Renal vein damage –
WIT warm ischemia time, SD standard deviation
Table 3 Postoperative outcomes
LOS including day of surgery, d, median (IQR) 5 (5–6)
Overall postop complications, no. (%) 16 (12.3 %)
Medical complications, no. (%) 5 (3.85 %)
AF pharmacologically cardioverted 2 (1.5 %)
Pneumonia 1 (0.8 %)
Pleural effusion 1 (0.8 %)
Deep venous thrombosis 1 (0.8 %)
Surgical complications, no. (%) 11 (8.5 %)
Postop transfusions only [Cl.2] 5 (3.85 %)
Selective embolization [Cl.3a] 3 (2.3 %)
Reoperation [Cl.3b] 1 (0.8 %)
Spleen rupture [Cl.4] 1 (0.8 %)
Fistula without stenting [Cl.1] 1 (0.8 %)
Fistula with stenting [Cl.3a] –
Acute renal failure, no. (%) 2 (1.5 %)
Delta hemoglobin, g/dl, mean (SD) 2.21 (1.81)
Delta creatinine, mg/dl, mean (SD) 0.06 (0.23)
LOS length of stay, AF atrial fibrillation, Cl. Clavien grade, SD
standard deviation, IQR interquartile range
Table 4 Pathology
Benign tumors, no. (%) 23 (17.7 %)
Malignant tumors, no. (%) 107 (82.3 %)
Histotype of malignant tumors, no. (%)
Clear cell RCC 68 (63.6 %)
Papillary RCC type 1 15 (14.0 %)
Papillary RCC type 2 6 (5.7 %)
Chromophobe RCC 17 (15.9 %)
Collecting duct RCC 1 (0.8 %)
Fuhrman grade in clear cell RCC, no. (%)
Grade 1–2 59 (86.7 %)
Grade 3–4 9 (13.3 %)
Pathological T stage, no. (%)
T1a 70 (65.4 %)
T1b 25 (23.4 %)
T2a 1 (0.9 %)
T3a 11 (10.3 %)
Pathological diameter, cm, mean (SD) 3.0 (1.5)
Positive surgical margins, no. (%) 3 (2.8 %)
RCC renal cell carcinoma, SD standard deviation
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At pathological assessment, benign tumors resulted in
23 (17.7 %) patients. Of the 107 confirmed malignant
lesions, 68 were conventional clear cell carcinoma
(63.6 %), 21 papillary (19.6 %), 17 chromophobe
(15.9 %), and 1 collecting duct RCC. Mean ± SD patho-
logical diameter was 3.0 ± 1.5 cm. Pathological stage was
pT1a in 70 cases (65.4 %), pT1b in 25 (23.4 %), pT2a in 1
(0.9 %), and pT3a in 11 (10.3 %) cases. Fuhrman nuclear
grade in clear cell RCC resulted 1–2 in 59 (86.7 %)
patients, and 3–4 in 9 (13.3 %). Positive surgical margin
(PSM) occurred in 3 patients (2.8 %) (Table 4).
At a mean (median, range) follow up of 24 months (25,
12–42), all patients were alive, one patient had distant
relapse with stable disease under antiangiogenetic therapy.
No local recurrences were observed.
In the same period, 67 SE were performed laparoscop-
ically without the robotic assistance and of those 93 %
were cT1a (63 cases). A sub analysis of cT1a tumors
showed no statistically significant differences between the
laparoscopic SE group and the ERASE group for age,
gender, BMI, clinical diameter, nephrometric score, pre-
operative hemoglobin, and creatinine (Table 5). However,
all the laparoscopic procedures were elective versus
94.5 % of ERASEs (p = 0.05) (Table 5). A comparison of
intra and postoperative outcomes among laparoscopic SE
and ERASE procedures is reported in Table 6. Overall, a
clampless procedure was more frequently performed in
case of ERASE than during laparoscopic SE (35.4 vs.
17.5 %; p = 0.01) and in case of pedicle clamping, median
WIT was significantly shorter after ERASE than after
laparoscopic SE (17.3 vs. 20.3 min.; p = 0.02) (Table 6).
Median EBLs was significantly lower in the ERASE group
than during laparoscopic SE (111 vs. 170 ml; p \ 0.0001)
(Table 6). Median operative time was comparable between
the two groups (Table 6). Intraoperative complications rate
was similar between the two groups (Table 6).
Concerning postoperative data, surgical complication
rates were comparable between ERASE and laparoscopic
SE (6.9 vs. 7.9 %) with a significantly higher incidence of
urinary fistulas requiring stent insertion in the laparoscopic
SE group (6.3 %) in comparison to the ERASE group
Table 5 Patient demographics and preoperative parameters of
patients with cT1a tumors undergoing ERASE or laparoscopic SE
Preoperative data
(cT1a group)
Laparoscopic SE ERASE p
Age, year; mean (SD) 59.3 (12.5) 62.9 (10.7) 0.06
Sex, no. (%) 0.89
Male 38 (60.3 %) 62 (58.5 %)
Female 25 (39.7 %) 39 (38.6 %)
BMI, median (IQR) 25.8 (23.2–28.1) 25.5 (23.2–28.1) 0.08
ASA score, no. (%) 0.12
0–2 60 (95.2 %) 91 (90.1 %)
3 3 (4.8 %) 10 (9.9 %)
Charlson index,
median (IQR)
1 (0–1) 1 (0–1) 0.77
Clinical diameter, cm,
mean (SD)
2.4 (0.9) 2.5 (0.8) 0.23
PADUA score,
median (IQR)
7 (6–8) 7 (6–8) 0.83
Indication, no. (%)
Absolute/relative 0 6 (5.5 %) 0.05
Elective 63 (100.0 %) 95 (94.5 %)
Preoperative
hemoglobin,
g/dl, mean (SD)
14.6 (1.4) 14.1 (1.5) 0.12
Preoperative creatinine,
mg/dl mean (SD)
0.8 (0.1) 0.8 (0.2) 0.58
BMI body mass index, ASA American Society of Anesthesiologists
class risk, SD standard deviation, IQR interquartile range
Table 6 Intraoperative and postoperative outcomes of patients with
cT1a tumors undergoing ERASE or laparoscopic SE
Intraoperative data (cT1a
group)
Laparoscopic
SE
ERASE p
Clamping, no. (%) 0.01
Yes 52 (82.5 %) 64
(64.6 %)
No 11 (17.5 %) 35
(35.4 %)
WIT of pedicle/renal artery
clamping, min. mean (SD)
20.3 (6.9) 17.3 (5.6) 0.02
Estimated blood loss, ml.
Mean (SD)
170 (130.6) 111 (95.0) \0.0001
Operating time, min 146.2 (45.3) 153.4
(50.1)
0.50
Total intraoperative
complications, no. (%)
1 (1.6 %) 1 (1.0 %) 0.85
Days to drainage removal,
mean (SD)
4.3 (2.8) 2.8 (1.3) 0.03
LOS including day of
surgery, median (IQR)
6 (3-8) 5 (4-6) 0.05
Overall postop
complications, no. (%)
5 (7.9 %) 9 (8.9 %) 0.01
Medical complications, no.
(%)
0 2 (2.0 %) 0.81
Surgical complications, no.
(%)
5 (7.9 %) 7 (6.9 %) 0.26
Urinary fistula treated with
stenting, n. %
4 (6.3 %) 1 (1.0 %) 0.05
Selective embolization, n. % 0 2 (2.0 %) 0.52
Delta hemoglobin, g/dl 2.2 (1.3) 2.3 (1.9) 0.81
Delta creatinine, mg/dl 0.1 (0.2) 0.1 (0.2) 0.65
PSM rate 1.8 % 2.2 % 0.45
SD standard deviation, IQR interquartile range, WIT warm ischemia
time, LOS length of stay, PSM positive surgical margin
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(1 %). Indeed, mean time to drainage removal (p = 0.03)
and overall hospital stay (p = 0.05) were significantly
lower in the ERASE group compared to the laparoscopic
approach. Groups were comparable also in terms of PSMs
rate.
Discussion
RAPN may overcome the technical limitations of LPN due
to three-dimensional visualization associated with the En-
doWrist technology that allows for excellent vision of the
operative field and the possibility of dissecting the tissue
optimally by varying the degree of incidence with the
target structures [10–15]. Moreover, we confirm at least in
cT1a that RAPN can provide equivalent oncological results
to LPN with the further advantage of significantly lower
the need for clamping, WIT, EBL, and LOS [11, 20].
ERASE represents the transposition of open SE to
robotic surgery and is becoming the standard technique of
NSS in our institution.
SE as a conservative approach in the management of
intracapsular renal masses has gained ever more accep-
tance among urologists [3–6, 16–18, 21, 22]. This tech-
nique consists in removing the tumor by blunt dissection,
using the natural cleavage plane between the tumor and
normal parenchyma, without a visible rim of healthy tissue
around it.
SE technique provides excellent perioperative results
and a low surgical complications rate. In a prospective
series of 200 consecutive patients who had open SE, we
reported a low rate of Clavien grade III surgical compli-
cations such as urinary fistula requiring JJ stent positioning,
that was 0.5 %, and postoperative bleeding requiring su-
perselective embolization of renal artery, that occurred in
2 % of cases [18]. These data compare favorably with the
rates reported after standard PN in the best available evi-
dence, that is 4.4 % for urinary fistula and 3.1 % for severe
postoperative bleeding [23].
Possible explanation of this evidence might be that SE
technique, resecting no renal parenchyma around the
tumor, causes the slightest unnecessary deepening of the
excision in healthy tissues, resulting in a lower theoretical
risk of postoperative bleeding and laceration of the urinary
collecting system that can cause the development of uri-
nary fistulas.
In the present series, we recorded a relatively low rate of
overall perioperative complications (13.1 %), with a 3.9 %
of Clavien grade III–IV surgical postoperative complica-
tions, which are consistent with prior published robotic
series [20, 24].
Some authors in the past have expressed skepticism
about the risk of PSM during SE and the risk of local
recurrence resulting from inadequate tumor excision or
tumor multifocality closely related to the main tumor [25–
27]. However, good oncologic, functional and periopera-
tive outcomes were reported in some large, retrospective
series of SE with long-term follow up and we confirm in
the present series that ERASE in oncologically safe with no
local recurrences at a short term follow up (mean 24, range
12–42 months) [4–6, 16–18].
Recently, a multicentric study conducted by the Sur-
veillance and Treatment Update Renal Neoplasms (SAT-
URN) project, promoted by the Italian Society of Urology
that collected data of 1519 patients from 16 academic
centers in Italy, showed no statistically difference in terms
of progression-free survival, cancer specific survival esti-
mates and local recurrence rate between patients treated
with SE and standard PN for RCC. Interestingly, the
reported PSM rates in the traditional PN group were sig-
nificantly higher than those reported in the SE group [28].
In a prospective series of 164 patients with RCC who
underwent open SE with no ablation of the tumor bed, we
reported no PSM and a local recurrence rate at the enu-
cleation site of 0.6 %, that is in perfect harmony with those
reported in the literature after standard PN. This study
demonstrates the oncological safety of SE without the
presence of the tumor bed ablation bias [17].
A recent prospective study based on pathologic exami-
nation of the surgical specimen obtained after SE provided
the pathologic rationale of SE. In this study we described
that all RCCs suitable for NSS are surrounded by a con-
tinuous, not fenestrated fibrous pseudocapsule. This perit-
umoral pseudocapsule can be penetrated irrespective of
tumor size, with a reported infiltration rate of 26.6 % on the
parenchymal side, but the presence of a thin layer of
parenchymal tissue, not macroscopically detectable, sepa-
rates neoplastic cells from the enucleation bed and allows
for negative surgical margins, also if no efforts are made to
leave a rim of healthy kidney tissue around the neoplasm
[3]. This microscopic layer of renal parenchyma make it
possible to consider SE as a minimal PN [3, 21, 29].
Therefore, if the surgeon follows the natural cleavage plane
between tumor pseudocapsule and kidney parenchyma by
blunt dissection, thus performing a SE, there is a limited
risk of PSM even with larger masses.
This data has been confirmed by our paper on prognostic
role of pseudocapsule infiltration, in which emerges that
neoplastic infiltration of pseudocapsule on the parenchymal
side does not increase the risk of having a local or systemic
recurrence [30].
The 3D vision and the EndoWrist also help to decrease
the PSM as they typically provide optimal dissection
angles [10–15]. Moreover, a faster and precise removal
step, without the need of repositioning the kidney to
achieve an incidental angle, that is mandatory during LPN,
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allows the surgeon to perform a more ergonomic and
‘intuitive’ tumorectomy and to approach even more diffi-
cult cases, such as large, intraparenchymal or perihilar
tumors [12–15]. In these latter cases, when the depth of the
lesion or the proximity to important vascular structures
makes the procedure more challenging, the adoption of the
SE technique can be decisive, as the blunt dissection pro-
vides a clear dissection plane identification, helping the
surgeon to discriminate the natural cleavage plane existing
between the tumor and the renal parenchyma, and ‘‘to stay
close’’ to the pseudocapsule allows the surgeon to avoid
entering into the tumor.
The advent of the robotic platform has certainly changed
and will change the conservative renal surgery. In fact, the
RAPN has reduced the technical gap of traditional lapa-
roscopy allowing to achieve surgical results superior to
those of LPN, especially by reducing the WIT, EBL, and
LOS as showed in the present series [11]. Furthermore, the
robotic approach allowed to remove the lesions with a
significantly lower need for clamping the renal pedicle in
comparison to laparoscopic SE. In the present series,
ERASE with no pedicle clamping was used in 33.9 % of
patients, while arterial clamping or selective clamping of
the isolated arterial branch were used in 66.1 % of patients,
with a mean ± SD WIT of 18 ± 6 min.
The combination of robotic surgery with the SE, ERASE
technique, might be considered a further evolution of the
NSS, in which the maximum preservation of the renal
parenchyma, less WIT, less incidental calyceal tearing or
vascular injuries, together with the advantages of minimal
invasiveness, were obtained.
The pursuit of natural cleavage plane existing between the
tumor and the renal parenchyma might be difficult in smaller
and exophytic lesions, so it should not be mandatory for the
success of the procedure, but we believe that this technique
could be very helpful in complex cases such as large tumors,
hilar or centrally located lesions, in order to reduce the risk of
damage to noble structures in the renal sinus.
Limitations of the present study include the relatively
few patients enrolled, considering that robotic program has
started in our institution since January 2010. Moreover, in
the first part of the learning curve, many factors such as
tumor size, nephrometric score, and surgeon experience
might have influenced the decision to perform the proce-
dure in open fashion. However, at our knowledge, this is
the sole prospective series of patients, who had NSS per-
formed by SE with the robotic approach.
Conclusions
In our experience, the ERASE has proved to be a feasible
and oncologically safe technique for the minimal invasive
treatment of clinical stage T1 renal masses. ERASE exe-
cution is not a priority even if, in complex cases, such as
hilar or endophytic lesions, it leads to an unquestionable
advantages compared to a standard RAPN allowing a
greater preservation of adjacent structures. Overall, the
ERASE is associated with a low risk of postoperative
complications and as in the open SE does not imply an
increased risk of PSM compared to standard PN. Finally,
the robotic approach can achieve surgical results superior
to those of pure laparoscopy by reducing the need for
clamping, WIT, EBL, and LOS.
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